Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer-Reference-Cited by-同舟云学术

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Published:2006-05 Issue:5 Volume:3 Page:269-280
ISSN:1743-4254
Container-title:Nature Clinical Practice Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Nahta Rita,Yu Dihua,Hung Mien-Chie,Hortobagyi Gabriel N,Esteva Francisco J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,General Medicine

Link

http://www.nature.com/articles/ncponc0509.pdf

Reference105 articles.

1. Carter P et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289

2. Slamon DJ et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182

3. Slamon DJ et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712

4. Esteva FJ et al. (2005) Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7: 436–443

5. Joensuu H et al. (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9: 923–930

Cited by 760 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus;Frontiers in Immunology;2024-08-12

3. PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives;Journal of Clinical Medicine;2024-06-13

4. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab;Breast Cancer: Targets and Therapy;2024-05

5. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab <i>via</i> Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity;Biological and Pharmaceutical Bulletin;2024-04-15